Receptor News and Research

RSS

Study: Vitamin D directly terminates production of MS-causing protein

While for years scientists have noted an association between levels of vitamin D in a person's body and the person's ability to resist or minimize the effects of multiple sclerosis (MS), the mechanism involved has not been established.

17 Aug 2011

Curis initiates CUDC-101 Phase I combination trial in advanced head and neck cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the first patient has been treated in a Phase I combination trial of CUDC-101.

17 Aug 2011

Study confirms that vitamin D deficiency increases aggressiveness of colon cancer

A study conducted by VHIO researchers confirms that a lack of vitamin D increases the aggressiveness of colon cancer.

16 Aug 2011

Pfizer, QIAGEN partner to develop diagnostic-therapeutic combination for NSCLC

QIAGEN today announced it has entered into a partnership with Pfizer Inc. for the development of a companion molecular diagnostic test for use with an investigational Pfizer compound in global clinical development for treatment of non-small cell lung cancer.

From QIAGEN Manchester Limited 16 Aug 2011

Tel Aviv University scientists work to determine how H1N1 becomes pandemic

The last century has seen two major pandemics caused by the H1N1 virus - the Spanish Flu in 1918 and 2009's Swine Flu scare, which had thousands travelling with surgical masks and clamoring for vaccination. But scientists did not know what distinguished the Swine Flu from ordinary influenza in pigs or seasonal outbreaks in humans, giving it the power to travel extensively and infect large populations.

16 Aug 2011

AHRQ's new Spanish-language guide on heart medications

A free, illustrated easy-to-read pamphlet that compares drugs for preventing heart attacks, heart failure or strokes in people with stable coronary heart disease is one of six new Spanish-language publications from HHS' Agency for Healthcare Research and Quality that help patients compare treatments for common illnesses.

16 Aug 2011

Amorfix provides update on cancer therapeutic antibody programs

Amorfix Life Sciences Ltd., a product development company focused on diagnostics and therapeutics for misfolded protein diseases, provides an update on its cancer therapeutic antibody programs.

12 Aug 2011

Single engineered protein blocks two related angiogenic receptors

Cancer needs blood. In fact, some cancer medications work solely to slow or prevent cancer cells from creating new capillaries, choking off their much-needed blood and nutrient supply to halt the growth of tumors.

12 Aug 2011

Scientists identify new therapeutic target for ADHD, other neuropsychiatric disorders

A biochemical pathway long associated with diarrhea and intestinal function may provide a new therapeutic target for treating ADHD other neuropsychiatric disorders, according to a team of scientists from China and the United States reporting Aug. 11 in Science.

12 Aug 2011

FDA assigns PDUFA action date for review of Affymax peginesatide NDA

Affymax, Inc. today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2012 for the review of the investigational agent peginesatide New Drug Application.

12 Aug 2011

SIGMAR1 gene mutation associated with development of juvenile ALS

Researchers from the Kingdom of Saudi Arabia have identified a mutation on the SIGMAR1 gene associated with the development of juvenile amyotrophic lateral sclerosis.

12 Aug 2011

Blocking type 2 receptor reduces PDA cell growth with the activation of AMPK enzyme

Pancreatic cancer researchers at Thomas Jefferson University have shown, for the first time, that blocking a receptor of a key hormone in the renin-angiotensin system (RAS) reduces cancer cell growth by activating the enzyme AMPK to inhibit fatty acid synthase, the ingredients to support cell division.

11 Aug 2011

Researchers identify novel sensory pathway that modulates pro-inflammatory cells

New research led by Derya Unutmaz, MD associate professor, the Departments of Pathology, Medicine, and Microbiology at NYU School of Medicine and Mark Sundrud, PhD, of Tempero Pharmaceuticals, Inc., has identified a novel sensory pathway that modulates the potency of Th17 cell responses.

11 Aug 2011

Neoprobe seeks FDA marketing approval of Lymphoseek for use in ILM oncology procedure

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced it has submitted a New Drug Application (NDA) for Lymphoseek to the U.S. Food and Drug Administration.

11 Aug 2011

Positive results from two ADL5945 Phase 2 studies for opioid-induced constipation

Adolor Corporation today announced positive, statistically significant top line results from its two Phase 2 studies of ADL5945 in chronic non-cancer pain patients with opioid-induced constipation.

11 Aug 2011

Scientist determines how nyctalopin gene makes night vision possible

A scientist from the Florida campus of The Scripps Research Institute has determined how a particular gene makes night vision possible. The study, which was published in the August 10, 2011 edition of The Journal of Neuroscience, focuses on a gene called nyctalopin. Mutations in the gene result in inherited "night blindness," a loss of vision in low-light environments.

10 Aug 2011

BIDMC researchers receive PCF Challenge Awards for novel prostate cancer study

Beth Israel Deaconess Medical Center (BIDMC) researchers Martin Sanda, MD, and Steven Balk MD, PhD, have been awarded Challenge Awards of $1 million each from the Prostate Cancer Foundation (PCF) to lead two cross-disciplinary teams of investigators in their pursuit of new treatments for patients with advanced prostate cancer.

10 Aug 2011

Researchers demonstrate contribution of Immunoglobulin E to atherogenesis

There is an observed correlation between Immunoglobulin E (IgE) levels atherosclerosis, with twice amount of IgE present in patients with acute myocardial infarction as in patients with stable angina or without coronary heart disease (CHD). Guo-Ping Shi, DSc, Jing Wang, MD, PhD, and colleagues in the Department of Medicine at Brigham and Women's Hospital (BWH), have demonstrated the direct participation of IgE in atherogenesis in a mouse model.

10 Aug 2011

Flatworms provide new insight into organ regeneration, evolution of mammalian kidneys

Our bodies are perfectly capable of renewing billions of cells every day but fail miserably when it comes to replacing damaged organs such as kidneys. Using the flatworm Schmidtea mediterranea-famous for its capacity to regrow complete animals from minuscule flecks of tissue-as an eloquent example, researchers at the Stowers Institute for Medical Research demonstrated how our distant evolutionary cousins regenerate their excretory systems from scratch.

10 Aug 2011

GTx reports revenue of $1.6 million for second quarter 2011

GTx, Inc. today reported financial results for the second quarter of 2011. The net loss for the quarter ended June 30, 2011 was $10.7 million compared with a net loss of $12.9 million for the quarter ended June 30, 2010.

9 Aug 2011

Receptor News and Research

Study: Vitamin D directly terminates production of MS-causing protein

Curis initiates CUDC-101 Phase I combination trial in advanced head and neck cancer

Study confirms that vitamin D deficiency increases aggressiveness of colon cancer

Pfizer, QIAGEN partner to develop diagnostic-therapeutic combination for NSCLC

Tel Aviv University scientists work to determine how H1N1 becomes pandemic

AHRQ's new Spanish-language guide on heart medications

Amorfix provides update on cancer therapeutic antibody programs

Single engineered protein blocks two related angiogenic receptors

Scientists identify new therapeutic target for ADHD, other neuropsychiatric disorders

FDA assigns PDUFA action date for review of Affymax peginesatide NDA

SIGMAR1 gene mutation associated with development of juvenile ALS

Blocking type 2 receptor reduces PDA cell growth with the activation of AMPK enzyme

Researchers identify novel sensory pathway that modulates pro-inflammatory cells

Neoprobe seeks FDA marketing approval of Lymphoseek for use in ILM oncology procedure

Positive results from two ADL5945 Phase 2 studies for opioid-induced constipation

Scientist determines how nyctalopin gene makes night vision possible

BIDMC researchers receive PCF Challenge Awards for novel prostate cancer study

Researchers demonstrate contribution of Immunoglobulin E to atherogenesis

Flatworms provide new insight into organ regeneration, evolution of mammalian kidneys

GTx reports revenue of $1.6 million for second quarter 2011

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News